---
title: Johnson & Johnson (JNJ)
layout: default
nav_order: 24
---

# Johnson & Johnson
{: .fs-9 }

{: .label .label-purple }

Moat: 4/5

{: .label .label-blue }

Understandability: 2/5

{: .label .label-green }

Balance Sheet Health: 5/5

## Business Overview
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=JNJ+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/JNJ/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning }
>The moat, understandability, and balance sheet health scores reflect a conservative evaluation to ensure a margin of safety in any assessment.


Certainly! Let's delve into Johnson & Johnson (JNJ) and assess its moat, financials, and overall business profile.

## Johnson & Johnson (JNJ) | Moat: 4 / 5 | Understandability: 2 / 5 | Balance Sheet Health: 5 / 5

## Business Overview
 {: .highlight}
Johnson & Johnson (JNJ) is a global healthcare giant with operations spanning pharmaceuticals, medical devices, and consumer health products. It’s a diversified company known for its strong brands and extensive global reach. 

### Revenues Distribution
 {: .new}
JNJ’s revenue is distributed across three segments:
1.  **Innovative Medicine (Pharmaceuticals):** Develops and markets prescription medications. This segment is primarily in immunology, oncology, neuroscience, infectious diseases and cardiovascular diseases.
2. **MedTech:** Develops and markets surgical, orthopaedic, vision, interventional solutions, and advanced technologies, including robotics.
3. **Consumer Health**: Offers over-the-counter drugs, skin care, baby care, wound care, and other wellness products.
    
  *Note:* In late 2023, JNJ spun off the consumer health business into a new publicly traded company named Kenvue. Going forward, JNJ's report will show Kenvue as a discontinued operations, so focus will be on the other two segments.*

### Industry Trends

1.  **Pharmaceuticals:**
     * Continued innovation and development of new drugs is crucial, with increased interest in biologics, cell, and gene therapies.
     * There is growing attention on drug pricing.
     * The use of AI and data analytics is rising in drug development and clinical trials.
     * There is an increasing trend towards personalized medicine.
2.  **MedTech:**
     * The industry is seeing a shift towards minimally invasive procedures, including robotic surgery.
     * There is a growing demand for data analytics and AI to improve patient outcomes.
    * The use of implants with advanced technologies.
    * The move to remote patient monitoring is another trend.
3. **Consumer Health:**
     * Preference for wellness and preventive care.
    * Strong competition from direct-to-consumer brands and private labels.
    * Rising use of digital platforms and e-commerce for purchasing healthcare products.
     * Focus on natural and environmentally friendly products.

### Competitive Landscape
JNJ operates in highly competitive environments across all its segments.

*  **Pharmaceuticals:** Faces intense rivalry from other pharmaceutical giants (e.g., Pfizer, Merck, AbbVie), as well as from biotech companies. Patent expirations and generic drugs pose constant threats to sales.
*  **MedTech:** Competes with other large MedTech companies (e.g., Medtronic, Stryker), medical technology startups, and smaller companies focusing on niche products.
*  **Consumer Health:** Competes with many established players (e.g., Procter & Gamble, Unilever) and emerging direct-to-consumer brands. Brand loyalty and pricing are key competitive factors.
  *Now JNJ operates only in Pharmaceutical and MedTech. They are leaders in their respective fields.*

### What Makes JNJ Different?
{: .important}
Johnson & Johnson stands out due to several factors:

*  **Diversification:** JNJ operates across multiple healthcare sectors, thus reducing its reliance on any single business. (But now JNJ is focusing only on pharma and medtech). 
*   **Strong Brands:** JNJ has a portfolio of well-known and trusted brands across all the segments.
*   **Global Scale:**  It has a vast international presence and an extensive distribution network, allowing for broad market access.
*   **R&D Expertise:** JNJ invests heavily in research and development, allowing it to innovate in both pharmaceuticals and medical devices.
*   **Integrated Healthcare Approach:** JNJ is among the companies that have a complete healthcare chain from manufacturing drug to treatment and devices to wellness.
*   **Stringent Quality Control:** As a healthcare provider, strict quality controls can enable better trust and reliability in the product portfolio.
*   **Financial Strength:** The company maintains a robust balance sheet.
*   **M&A Expertise:** JNJ has great experience in successful M&A and divestment.

### Recent Concerns / Controversies / Problems
{: .warning}
JNJ, being a massive organization, has had certain challenges:

*   **Opioid Litigation:** JNJ faced significant legal challenges and financial burdens related to its involvement in the opioid crisis. The company had to pay billions in settlement fees, which can impact future finances. The company is still facing litigations.
*   **Baby Powder Lawsuits:** JNJ faced thousands of lawsuits alleging that its talc-based baby powder caused cancer. The company has reached settlements and has announced a plan to reorganize its business through bankruptcy. This saga will continue to be a risk in the near term.
*   **Pricing Pressure:** In its pharmaceutical business, JNJ faces pricing pressures as governments and payers increase efforts to lower the cost of healthcare.

#### Management's Perspective

On calls, JNJ’s management has repeatedly emphasized:

*    **Commitment to innovation:** They continue to invest heavily in R&D to bring innovative drugs and medical devices into the market.
*   **Operational Excellence:**  They are focusing on improving operational efficiency to maximize profits and returns.
*    **Strategic Acquisitions:** JNJ is committed to pursuing strategic acquisitions to strengthen its position in certain key areas.
*   **Portfolio Management:** They actively manage their portfolios, making a decision on when to sell, spin off or hold certain businesses and products.

## Moat Assessment 4 / 5
{: .highlight}
JNJ's economic moat is assessed as strong due to several sources:

1.  **Intangible Assets (Brands and Patents):** JNJ’s brands have a high degree of customer loyalty. Moreover, a lot of its medical and pharmaceutical products are patent-protected and offer a sustainable competitive advantage.
2. **Switching Costs:** MedTech products come with long-term relationships with hospitals, and once adopted, it is costly to switch. Also, pharmaceutical products usually create dependencies among patients on their routine drugs, and thus, the rate of switching from the same product will be low.
3. **Size and Scale Advantages:** JNJ’s operations are global and diverse, with economies of scale that give it a competitive edge over smaller players.
4. **Proprietary Data**: As a healthcare company, the data generated about the usage of its products, will help improve the existing products and make newer ones better and faster.
*While JNJ enjoys a wide economic moat, the competitive nature of its businesses, potential disruption and regulations do reduce its width.

## Legitimate Risks that Could Harm the Moat
{: .important}
Despite its solid advantages, JNJ faces several potential risks that could weaken its moat:

1. **Patent Cliff:** The expiration of patents on key drugs exposes them to generic competition, which would affect the revenues considerably.
2.  **Increased Regulation:** The company faces increasing government regulation and healthcare reforms, which can increase compliance costs, limit pricing power, or mandate changes in its business practices.
3.  **Litigation Risks:** The company faces huge lawsuits, especially related to product liability and the opioids crisis which could lead to significant liabilities and reputational damage.
4. **Disruptive Technology:** New technologies and medical devices, may disrupt and displace JNJ's existing products and offerings.
5.  **Changes in Consumer Preferences:** Consumer health products are subject to changing trends and preferences, and brands can lose their competitive positions if they fail to adapt.
6. **Pricing Pressures:** Increased government and insurer efforts to control healthcare costs can limit price increases, affecting margins.
7.   **Increased Competition**: Increased competition in pharmaceuticals, medical devices, and consumer health industries, could also put a negative pressure on growth and profit potential.

## Business Resilience
Despite the risks mentioned above, JNJ demonstrates a high level of business resilience:

*  **Diversified Business Model:** The company’s business units are largely independent of each other, allowing them to overcome individual hurdles more easily. 
*  **Strong R&D:** JNJ is a company that has a strong ability to innovate new products and come out with new versions of the existing ones, so a product failure does not put a dent in the company’s overall prospects.
*  **Global Scale:** The geographical diversity of the business operations will give it access to various markets and reduce the risk associated with adverse conditions in any single region. 
*  **Financial Stability:** JNJ’s strong balance sheet gives it the resources to make required changes and stay stable in difficult times.

## Financials Analysis
{: .highlight}

### Income Statement
*   **Revenues:** JNJ’s annual revenue is about $80-90 billion and it has been steadily growing, with strength in its Pharmaceutical segment.
*   **Gross Profit Margin:** The company’s gross profit margin usually fluctuates around 70%.
*    **Operating Margin**: The operating margin tends to hover around 25%.
*   **Net Income:** JNJ’s net income is usually about $17-20 billion annually.

### Balance Sheet Health: 5 / 5

*   **Assets**: The company has about $180 billion in total assets and over $20B in cash. 
*   **Debt**: Their debt is a bit high at around $30B, but it can easily be paid off through their annual cash flow.
*  **Equity:** Total shareholders' equity is about $130B.
*   **Liquidity:** The company’s current ratio (current assets divided by current liabilities) is around 1.4, indicating a sound capacity to handle short term liabilities.

Overall, JNJ's balance sheet is very strong and they can easily tackle any problem that they may face.

### Understandability: 2 / 5
{: .important}

JNJ's business is quite complex to understand due to various factors:
*   **Business Segments:** JNJ has multiple businesses across different fields in healthcare (pharmaceuticals, medical devices, and consumer health). Each of these segments is complex, and it can make understanding their interplay difficult.
*  **Large Global Operations:** The company's extensive worldwide presence increases complexity, since local conditions, regulations, and market dynamics influence the business in various regions differently. 
*   **Financials:** Given the large scope and multiple segments of the company, analyzing the financial statements becomes more intricate. Multiple accounting adjustments, and non-recurring expenses are harder to understand.

**In Conclusion**
Johnson & Johnson is a resilient and stable company with a strong economic moat and sound financials. Its diversified business strategy, coupled with a focus on innovation and strong brands, contributes to its long-term stability. However, the company faces challenges related to litigation, competition, regulation, and ethical issues. The company has significant operations, numerous subsidiaries, complex accounting rules and financial statements, which makes it difficult to understand fully.